# IMM-BCP-01 in Mild to Moderate COVID-19

> **NCT05429021** · PHASE1 · TERMINATED · sponsor: **Immunome, Inc.** · enrollment: 9 (actual)

## Conditions studied

- SARS-CoV2 Infection
- COVID-19

## Interventions

- **DRUG:** IMM-BCP-01
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05429021
- **Lead sponsor:** Immunome, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-06-03
- **Primary completion:** 2023-01-06
- **Final completion:** 2023-01-06
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Business decision to discontinue the study based on strategic prioritization.
- **Last updated:** 2024-09-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05429021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05429021, "IMM-BCP-01 in Mild to Moderate COVID-19". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05429021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*